Ryoo BY - Search Results

1

Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis.

Casadei-Gardini A, Rimassa L, Rimini M, Yoo C, Ryoo BY, Lonardi S, Masi G, Kim HD, Vivaldi C, Ryu MH, Rizzato MD, Salani F, Bang Y, Pellino A, Catanese S, Burgio V, Cascinu S, Cucchetti A. Casadei-Gardini A, et al. Among authors: ryoo by. J Cancer Res Clin Oncol. 2021 Dec;147(12):3665-3671. doi: 10.1007/s00432-021-03602-w. Epub 2021 Mar 20. J Cancer Res Clin Oncol. 2021. PMID: 33745079

2

Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients.

Park YH, Lee JJ, Ryu MH, Kim SY, Kim DH, Do YR, Lee KH, Oh SJ, Kim YK, Suh CW, Heo DS, Ryoo BY, Kim JK, Song HS, Lee WS, Kim HJ, Bang YJ, Yang SH, Sohn SK, Kang YK; Lymphoma Study Division of the Korean Cancer Study Group. Park YH, et al. Among authors: ryoo by. Ann Hematol. 2006 Apr;85(4):257-62. doi: 10.1007/s00277-005-0060-6. Epub 2006 Jan 17. Ann Hematol. 2006. PMID: 16416337

3

Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer.

Park YH, Lee JL, Ryoo BY, Ryu MH, Yang SH, Kim BS, Shin DB, Chang HM, Kim TW, Yuh YJ, Kang YK. Park YH, et al. Among authors: ryoo by. Cancer Chemother Pharmacol. 2008 Apr;61(4):623-9. doi: 10.1007/s00280-007-0515-7. Epub 2007 May 24. Cancer Chemother Pharmacol. 2008. PMID: 17522863 Clinical Trial.

4

Prognostic significance of p53 gene mutations and protein overexpression in localized gastrointestinal stromal tumours.

Ryu MH, Kang YK, Jang SJ, Kim TW, Lee H, Kim JS, Park YH, Lee SS, Ryoo BY, Chang HM, Lee JL, Yook JH, Kim BS, Lee JS. Ryu MH, et al. Among authors: ryoo by. Histopathology. 2007 Sep;51(3):379-89. doi: 10.1111/j.1365-2559.2007.02797.x. Histopathology. 2007. PMID: 17727479

5

A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.

Ryu MH, Kang WK, Bang YJ, Lee KH, Shin DB, Ryoo BY, Roh JK, Kang JH, Lee H, Kim TW, Chang HM, Park JO, Park YS, Kim TY, Kim MK, Lee WK, Kang HJ, Kang YK. Ryu MH, et al. Among authors: ryoo by. Oncology. 2009;76(5):326-32. doi: 10.1159/000209384. Epub 2009 Mar 23. Oncology. 2009. PMID: 19307738 Clinical Trial.

6

A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer.

Kim C, Lee JL, Ryu MH, Chang HM, Kim TW, Lim HY, Kang HJ, Park YS, Ryoo BY, Kang YK. Kim C, et al. Among authors: ryoo by. Invest New Drugs. 2011 Apr;29(2):366-73. doi: 10.1007/s10637-009-9363-0. Epub 2009 Dec 9. Invest New Drugs. 2011. PMID: 19997960 Clinical Trial.

7

Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib.

Yoo C, Ryu MH, Kang BW, Yoon SK, Ryoo BY, Chang HM, Lee JL, Beck MY, Kim TW, Kang YK. Yoo C, et al. Among authors: ryoo by. J Clin Oncol. 2010 Mar 20;28(9):1554-9. doi: 10.1200/JCO.2009.26.5785. Epub 2010 Feb 22. J Clin Oncol. 2010. PMID: 20177019

8

Sorafenib for recurrent hepatocellular carcinoma after liver transplantation.

Yoon DH, Ryoo BY, Ryu MH, Lee SG, Hwang S, Suh DJ, Lee HC, Kim TW, Ahn CS, Kim KH, Moon DB, Kang YK. Yoon DH, et al. Among authors: ryoo by. Jpn J Clin Oncol. 2010 Aug;40(8):768-73. doi: 10.1093/jjco/hyq055. Epub 2010 May 21. Jpn J Clin Oncol. 2010. PMID: 20494947

9

Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability.

Kim KP, Ryu MH, Yoo C, Ryoo BY, Choi DR, Chang HM, Lee JL, Beck MY, Kim TW, Kang YK. Kim KP, et al. Among authors: ryoo by. Cancer Chemother Pharmacol. 2011 Aug;68(2):285-91. doi: 10.1007/s00280-010-1479-6. Epub 2010 Oct 19. Cancer Chemother Pharmacol. 2011. PMID: 20957481

10

Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients.

Yoon DH, Ryu MH, Ryoo BY, Beck M, Choi DR, Cho Y, Lee JL, Chang HM, Kim TW, Kang YK. Yoon DH, et al. Among authors: ryoo by. Invest New Drugs. 2012 Apr;30(2):819-27. doi: 10.1007/s10637-010-9593-1. Epub 2010 Nov 23. Invest New Drugs. 2012. PMID: 21104107

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

289 results

Search Page

Filters